Showing results (21-30 of 43) with videos related to
Sort By:
Pageof 5
Cancer Immunology, Immunotherapy : CII|May 1, 1996
Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2M J Ehrke, S Verstovsek, G Zaleskis, et al.Cancer Immunology, Immunotherapy : CII|March 7, 1998
Doxorubicin plus tumor necrosis factor alpha combination treatments in EL4-lymphoma-bearing C57BL/6 miceM J Ehrke, S Verstovsek, P Ujházy, et al.Leukemia Research|April 3, 2007
Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosisM A Elliott, S Verstovsek, D Dingli, et al.Leukemia|August 2, 2016
A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosisS Verstovsek, M Talpaz, E Ritchie, et al.Leukemia|May 15, 2007
The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1J Pan, A Quintás-Cardama, T Manshouri, et al.International Journal of Laboratory Hematology|March 4, 2009
Plasma levels of JAK2 mRNA in patients with chronic myeloproliferative diseases with and without V617F mutation: implications for prognosis and disease biologyW Ma, H Kantarjian, X Zhang, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 25, 2009
Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatmentG S Falchook, F Vega, N H Dang, et al.European Journal of Cancer Care|May 25, 2013
A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndromeN Daver, A Vega-Ruiz, H M Kantarjian, et al.Leukemia|August 2, 2001
Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromeS Verstovsek, H Kantarjian, E Estey, et al.Leukemia|April 4, 2008
A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosisA Quintás-Cardama, W Tong, H Kantarjian, et al.Pageof 5